Effect of pepleomycin on peripheral lymphocytes.
The blood lymphocyte population was monitored in 6 patients with advanced malignant tumors who were treated with large doses of a new cytotoxic drug termed pepleomycin. It was observed that the size of the cell population, its cellular composition, mitogen stimulations and natural killer activity did not change in any consistent ways during or after treatment. It is concluded that pepleomycin does not directly affect the lymphocytic population.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007694:Killer Cells, Natural / Q000187:drug effects; D007890:Leiomyosarcoma / Q000188:drug therapy; D007958:Leukocyte Count; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D017663:Peplomycin; D013736:Testicular Neoplasms / Q000188:drug therapy; D013964:Thyroid Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D001761:Bleomycin; D017663:Peplomycin